Publication: Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma
Loading...
Program
KU-Authors
Organization Authors
Co-Authors
Zwimpfer, Tibor A
Ewald, Hannah
Jayawardana, Madawa
Appenzeller-Herzog, Christian
Bizzarri, Nicolò
Razumova, Zoia
Kacperczyk-Bartnik, Joanna
Heinzelmann-Schwarz, Viola
Friedlander, Michael
Bowtell, David DL
Date
Language
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors. Copyright © 2024 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.
Source
Publisher
John Wiley and Sons
Subject
Citation
item.page.haspartof
Source
Cochrane Database of Systematic Reviews
item.page.ispartofseries
item.page.edition
DOI
10.1002/14651858.CD015896
item.page.datauri
item.page.link
Rights
N/A
Copyrights Note
Rights and licensing
N/A